China Medical System Holdings Limited
0867
Ранг среди акций
#4775
Established in 1995 and headquartered in North Point, Hong Kong, China Medical... Established in 1995 and headquartered in North Point, Hong Kong, China Medical System Holdings Limited functions as an investment holding company with a primary focus on the development, marketing, and distribution of a wide array of pharmaceutical products throughout the People's Republic of China. The company's extensive portfolio addresses numerous therapeutic areas. Its cardiovascular offerings include Plendil for hypertension and stable angina, XinHuoSu for acute heart failure, and Imdur for coronary heart disease, chronic heart failure, and myocardial infarction prevention. For mental health and neurological support, it provides Deanxit to treat mild-to-moderate depression and anxiety, along with Parlodel tablets for endocrine and neuro system indications. Digestive and liver conditions are managed with products such as Ursofalk for gallstones and cholestatic liver disease, Salofalk for ulcerative colitis and Crohn's disease, Bioflor for diarrhea, Combizym for dyspepsia, and Ganfule capsules for primary liver cancer, plus MOVICOL for chronic constipation. The company also markets Augentropfen Stulln Mono eye drops for senile macula degeneration and asthenopia, Hirudoid for blunt trauma and superficial phlebitis, Elcatonin injection for osteoporosis, and Lamisil tablets for fungal infections. Respiratory issues are addressed by YiNuoShu, while infectious diseases benefit from DanShenTong capsules (for various infections like acne, tonsillitis, and boils) and YinlianQinggan granules for hepatitis. XiDaKang, a protein hydrolysate oral solution, is also part of its offerings. Beyond its pharmaceutical endeavors, the group is also actively involved in agriculture and livestock operations. China Medical System Holdings Limited operates as a subsidiary of Treasure Sea Limited.
Цена акции
$1.30
Рыночная капитализация
$3.17B
Изменение (1 день)
-1.93%
Изменение (1 год)
-23.27%
Страна
HK
Торговля China Medical System Holdings Limited (0867)
Категория
Healthcare
Коэффициент P/E для China Medical System Holdings Limited (0867)
Коэффициент P/E на October 2026 TTM: 14.33
Согласно последним финансовым отчетам и цене акций China Medical System Holdings Limited, текущий P/E (TTM) составляет 14.33. В конце 2023 у компании был P/E на уровне 12.62.
История P/E компании China Medical System Holdings Limited с 2006 по 2026
P/E на конец каждого года
| Год | P/E коэффициент | Изменить |
|---|---|---|
| 2026 (TTM) | 14.33 | 34.83% |
| 2024 | 10.63 | -15.81% |
| 2023 | 12.62 | 54.59% |
| 2022 | 8.16 | -5.85% |
| 2021 | 8.67 | 21.84% |
| 2020 | 7.12 | -43.87% |
| 2019 | 12.68 | 47.67% |
| 2018 | 8.59 | -61.87% |
| 2017 | 22.52 | 13.35% |
| 2016 | 19.87 | -16.07% |
| 2015 | 23.67 | 0.72% |
| 2014 | 23.50 | -6.23% |
| 2013 | 25.06 | 14.26% |
| 2012 | 21.93 | 29.37% |
| 2011 | 16.96 | -48.68% |
| 2010 | 33.04 | -0.72% |
| 2009 | 33.28 | 1,346.58% |
| 2008 | 2.30 | -36.83% |
| 2007 | 3.64 | -49.59% |
| 2006 | 7.22 | 0.00% |
P/E для схожих компаний или конкурентов
| Компания | P/E Ratio | Разница P/E | Страна |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | 143.92% |
IN
|
Как читать P/E Ratio?
Коэффициент цена/прибыль (P/E Ratio) отражает соотношение между ценой акции компании и её прибылью на акцию.
Низкий, но положительный P/E говорит о том, что компания приносит высокую прибыль при низкой оценке и может быть недооценена. Высокий отрицательный (близкий к 0) P/E указывает на значительные убытки.
Компании с P/E выше 30 или отрицательным считаются "акциями роста" — инвесторы ожидают роста или будущей прибыли.
Компании с положительным P/E ниже 10 считаются "ценностными акциями", т.е. уже прибыльны, но с низким потенциалом роста.